Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells - PubMed (original) (raw)
. 1997 Dec 19;272(51):32260-6.
doi: 10.1074/jbc.272.51.32260.
Affiliations
- PMID: 9405430
- DOI: 10.1074/jbc.272.51.32260
Free article
Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells
A T Ferguson et al. J Biol Chem. 1997.
Free article
Abstract
The cytosine analog 5-aza-2'-deoxycytidine is a potent inhibitor of DNA methyltransferase. Its cytotoxicity has been attributed to several possible mechanisms including reexpression of growth suppressor genes and formation of covalent adducts between DNA methyltransferase and 5-aza-2'-deoxycytidine-substituted DNA which may lead to steric inhibition of DNA function. In this study, we use a panel of human breast cancer cell lines as a model system to examine the relative contribution of two mechanisms, gene reactivation and adduct formation. Estrogen receptor-negative cells, which have a hypermethylated estrogen receptor gene promoter, are more sensitive than estrogen receptor-positive cells and underwent apoptosis in response to 5-aza-2'-deoxycytidine. For the first time, we show that reactivation of a gene silenced by methylation, estrogen receptor, plays a major role in this toxicity in one estrogen receptor-negative cell line as treatment of the cells with anti-estrogen-blocked cell death. However, drug sensitivity of other tumor cell lines correlated best with increased levels of DNA methyltransferase activity and formation DNA.DNA methyltransferase adducts as analyzed in situ. Therefore, both reexpression of genes like estrogen receptor and formation of covalent enzyme. DNA adducts can play a role in 5-aza-2'-deoxycytidine toxicity in cancer cells.
Similar articles
- A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, Davidson NE. Keen JC, et al. Breast Cancer Res Treat. 2003 Oct;81(3):177-86. doi: 10.1023/A:1026146524737. Breast Cancer Res Treat. 2003. PMID: 14620913 - Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine.
Karpf AR, Moore BC, Ririe TO, Jones DA. Karpf AR, et al. Mol Pharmacol. 2001 Apr;59(4):751-7. Mol Pharmacol. 2001. PMID: 11259619 - DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine.
Bovenzi V, Lê NL, Côte S, Sinnett D, Momparler LF, Momparler RL. Bovenzi V, et al. Anticancer Drugs. 1999 Jun;10(5):471-6. doi: 10.1097/00001813-199906000-00007. Anticancer Drugs. 1999. PMID: 10477167 - Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Stresemann C, Lyko F. Stresemann C, et al. Int J Cancer. 2008 Jul 1;123(1):8-13. doi: 10.1002/ijc.23607. Int J Cancer. 2008. PMID: 18425818 Review.
Cited by
- Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases.
Cheng X, Blumenthal RM. Cheng X, et al. Curr Opin Struct Biol. 2022 Aug;75:102433. doi: 10.1016/j.sbi.2022.102433. Epub 2022 Jul 29. Curr Opin Struct Biol. 2022. PMID: 35914495 Free PMC article. Review. - Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.
Wong-Brown MW, van der Westhuizen A, Bowden NA. Wong-Brown MW, et al. BMC Cancer. 2022 Jan 24;22(1):100. doi: 10.1186/s12885-022-09197-w. BMC Cancer. 2022. PMID: 35073851 Free PMC article. - Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia.
Saliba AN, John AJ, Kaufmann SH. Saliba AN, et al. Cancer Drug Resist. 2021;4(1):125-142. doi: 10.20517/cdr.2020.95. Epub 2021 Mar 19. Cancer Drug Resist. 2021. PMID: 33796823 Free PMC article. - Non-epigenetic induction of HEXIM1 by DNMT1 inhibitors and functional relevance.
Sharma V, Montano MM. Sharma V, et al. Sci Rep. 2020 Dec 3;10(1):21015. doi: 10.1038/s41598-020-78058-y. Sci Rep. 2020. PMID: 33273553 Free PMC article. - Lysophosphatidic Acid Receptor 6 (LPAR6) Expression and Prospective Signaling Pathway Analysis in Breast Cancer.
Tao K, Guo S, Chen R, Yang C, Jian L, Yu H, Liu S. Tao K, et al. Mol Diagn Ther. 2019 Feb;23(1):127-138. doi: 10.1007/s40291-019-00384-3. Mol Diagn Ther. 2019. PMID: 30694446
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical